MediciNova Supports NIH-Backed Trial for Neurodegenerative Treatment

MediciNova Supports NIH-Funded Expanded Access Clinical Trial for MN-166 (Ibudilast)

MediciNova, Inc., a clinical-stage biopharmaceutical company, has announced its support for an NIH-funded expanded access clinical trial involving MN-166 (ibudilast). MN-166 is a small molecule compound currently in late-stage clinical development targeting neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS), and degenerative cervical myelopathy (DCM). Additionally, it is being evaluated for glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder. The compound has also been tested in patients at risk of developing acute respiratory distress syndrome (ARDS).

MediciNova's Development Pipeline

MediciNova's lead asset, MN-166, is in Phase 3 trials for ALS and DCM and is Phase 3-ready for progressive MS. The company is also conducting Phase 2 trials for MN-166 in Long COVID and substance dependence. Another compound, MN-001 (tipelukast), has been evaluated in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF) and is undergoing a second Phase 2 trial for non-alcoholic fatty liver disease (NAFLD).

Forward-Looking Statements

The company warns that forward-looking statements regarding the future development and efficacy of its compounds involve risks and uncertainties. These include potential difficulties in securing funding, clinical trial risks, regulatory approval challenges, and reliance on third-party collaborations. MediciNova emphasizes the importance of not placing undue reliance on these statements, as they are subject to change.

Conclusion

MediciNova's support for the NIH-funded trial underscores its commitment to advancing treatments for neurodegenerative and inflammatory diseases. The company's strategic focus on developing MN-166 and MN-001 positions it to potentially address significant unmet medical needs across various conditions.